Highlights
KLSE: YSPSAH (7178)       Y.S.P. SOUTHEAST ASIA HOLDING BHD MAIN : Health Care
Last Price Today's Change   Day's Range   Trading Volume
2.63   -0.02 (0.75%)  2.63 - 2.63  10,100
Analyze this stock with MQ Trader system

Overview

Market Cap: 364 Million
NOSH: 138 Million
Avg Volume (4 weeks):93,336
4 Weeks Range:2.61 - 3.10
4 Weeks Price Volatility (%):
4.08%
52 Weeks Range:2.33 - 3.39
52 Weeks Price Volatility (%):
28.30%
Average Price Target: 3.86
Price Target Upside/Downside: +1.23
Stamp duty exempted for year 2018

Financial Highlight

Latest Quarter | Ann. Date 30-Sep-2018 [#3]  |  21-Nov-2018
Next QR | Est. Ann. Date: 31-Dec-2018  |  28-Feb-2019
T4Q P/E | EY: 12.71  |  7.87%
T4Q DY | Payout %: 2.65%  |  33.61%
T4Q NAPS | P/NAPS: 2.2158  |  1.19
T4Q NP Margin | ROE: 10.16%  |  9.34%

Headlines

Date Subject
21-Nov-2018 YSP Southeast Asia - 9M18 Within Expectations
07-Nov-2018 Technical Analysis - Y.S.P. Southeast Asia
26-Oct-2018 预算案值得关注的个股(四)- 医疗保健
07-Oct-2018 Potential Trade Idea with Pullback Strategy - Y.S.P. Southeast (7178)
03-Oct-2018 Trading Stocks - Y.S.P. Southeast Asia
01-Oct-2018 医药股前景可期?
25-Sep-2018 上升股:永信东南亚阻力RM3.45
25-Sep-2018 Technical Analysis - Y. S. P. Southeast Asia
23-Aug-2018 Technical Analysis - Y.S.P. Southeast Asia
16-Aug-2018 永信东南亚(YSPSAH)- 国内增长推动营收
14-Aug-2018 YSP Southeast Asia - Domestic Growth Surge Boosts 2Q18
14-Aug-2018 YSP Southeast Asia - Domestic Growth Surge Boosts 2Q18
31-Jul-2018 Technical Analysis - Y.S.P. Southeast Asia
29-Jul-2018 YSPSAH peer comparison analysis
19-Jul-2018 Technical Analysis - Y.S.P. Southeast Asia
17-Jul-2018 永信东南亚(YSPSAH)- 现有竞争地位,表明更高赢率
12-Jul-2018 YSP Southeast Asia - A Shot in the Arm
22-Jun-2018 YSP Southeast Asia - A Shot in the Arm
28-May-2018 YSP Southeast Asia - Good Start, Within Expectations
01-Mar-2018 YSP Southeast Asia - Core Net Profit Meets Expectations

Business Background

Y SP Southeast Asia Holding Bhd is an investment company, which engages in the pharmaceutical business, provision of management services. It operates through the following segments: Trading, Manufacturing and Investment Holding. The Trading segment imports, exports, and trades various kinds of pharmaceutical products. The Manufacturing segment manufactures pharmaceutical products. The Investment Holding segment focuses on investment holding activity. Firm’s majority revenue comes from the Manufacturing segment. Its majority revenue is concentrated in Malaysia.
Trade this stock with T+7 trading account. Find out more.

  4 people like this.
 
pundekman better buy. counter primed for bonus issue
23/08/2017 10:25
gcke For the period from year 2012 to 2016, YSP had came out top in earnings during the 2QR.In 2016,second with PAT RM 6.818m and 2012 top with PAT RM 4,542m.
2.But basing on recent development and initiatives taken by the company expects the revenue and earning streams to be enhanced and better than the prevues QR y-o-y or q-o-q.
26/08/2017 11:24
YTChoong Anyone know can share when is coming QR to be out?
29/08/2017 16:54
abang_misai result out. not bad this time
29/08/2017 17:14
kentg03 YoY n QoQ drop more than 50%
29/08/2017 17:54
Flintstones Holland!
29/08/2017 19:12
shpg22 1st half topline & bottomline both increased. Expect 3rd quarter bottomline to increase strongly (80-100% YoY). ACCUMULATE at fair price 3.25.
29/08/2017 19:23
skyea Ysp earnings is seasonal so qoq comparison is not meaningful. Yoy is the only way
29/08/2017 20:44
skyea Trailing 4 qtr earnings makes 2.87 share price 14.1 PE. Any knee jerk reaction to the bottom is going to give you 13 PE pharma company with highest margin, roe and roa
29/08/2017 20:50
skyea comparing Q2 for 2014, 2015, 2016, 2017, this quarter is very good. on par with last year. Q2 17= Q2 16, which is > Q2 15 and Q2 14
29/08/2017 22:50
Flintstones Investors should know now never extrapolate one quarter of good results
30/08/2017 10:14
shpg22 Overeaction by just 1 quarter. 1st half YoY revenue & profit still growing.
30/08/2017 10:39
necro fuhhh sell d @RM3.05 coz know that 2nd quarter is always the weakest quarter YoY..hopefully market correct more to level where can buy @ cheap price
30/08/2017 14:56
yansheng2213 clever =)
30/08/2017 18:04
shpg22 Time d market is a fools game...heard before
30/08/2017 20:05
gongkia i didnt check the price :P
31/08/2017 02:15
necro waaa down cheaper!!
05/09/2017 11:55
necro support broke!!gg.com liaooooo!!! horeyyyy!!
05/09/2017 11:55
gcke Seemed like the consolidation phase has been over after the big drop in the stock price on the release of the 2QR.
2.Today trend and move momentum for the price seemed to be positive.
3.Hopefully the support momentum can be sustained for the price to gradually move up.
4.The coming 3Qr should be better to support the price at the previous closing high or higher as what the analyst has written and expected.

Hope for better days.Always stay positive:-)))
19/09/2017 19:47
Evolution4 what internal news u know espesp?
27/09/2017 23:26
SYZZ anyone knws what is the doorgift for the AGM?
02/10/2017 11:17
gcke @SYZZ is the token gift of appreciation given out to all eligible shareholders or their proxies,nominees who register and attend the company AGM.
2.Can be in the form of KFC,White-town Coffee vouchers.Aji-No-Moto for example will issued out to all attendees the company products.The amount and quantities given out are in the value ranging from RM 30- RM 200.
3.Air Asia will give out free air travel ticket overseas.
4.Try attending on of such AGM to gather some good experience.In addition some companies like ICON,Astro,Air Asia,etc provide morning breakfast.Others like Malakoff also provide lunch pack.

Hope that explained.Smart investing:-)))
03/10/2017 13:43
FKLI13 What happen to YSP ? Keep on eating !
11/10/2017 16:33
michaelgoh Flying high, company doing well can buy
11/10/2017 16:39
kakashit The privatisation price of Hovid is at 38cents, 1.5 times of the net asset per share.

Ngam ngam YSP is also selling at 1.5 p/naps, given YSP has neglectable intangible asset, no dilution from warrants and also no record of manufacutring license revocation,

that's mean the real instrinsic value of YSP should fare better than Hovid.
12/10/2017 14:18
Anson Ang Qr must b bad.. Ppl throw
16/11/2017 16:48
Thkent91 Masuk Holland. Looks like all pharmaceutical company not doing any well. Long term RM 6
16/11/2017 19:49
Angel of KLSE 大马股仙 result not bad, why go hol land kan?
20/11/2017 13:21
kakashit Yes, share price might go to Holland, but the dividend will only go to ur bank acc
12/02/2018 10:35
Bitter Chocolate Super under value share, this company profile tell it worth more than u can imagine and the payout will come very soon. I stake all in..The history of this company tell May of each year is the best time to grab...Deviden + Share price soar all happening soon.
14/05/2018 12:09
PrincsX anyonw knw what is YSPSAH AGM doorgift for year 2017??? this year AGM location a bit far...
24/05/2018 12:41
k3nthiew https://www.thestar.com.my/business/business-news/2018/07/18/cimb-research-positive-on-ysp-southeast-asia-tp-rm3pt46/


CIMB also ask to buy now. More contracts from MoH won.
19/07/2018 09:58
thesteward Didn’t CIMB just up the tp to rm4 today?
14/08/2018 17:54
thesteward Really undervalue
14/08/2018 17:55
k3nthiew https://www.malaymail.com/s/1664223/health-protection-scheme-for-b40-group-for-implementation-next-year-says-dz

Health insurance scheme will expanded to Middle 40 too... Hope Ysp can get more market share...
21/08/2018 08:56
Yael Jasper Good time to accumulate more and gain more profit :)
21/08/2018 11:20
TANCHEECHIM (File pix) Photo shows a man getting a health check from a medical personnel. The Health Ministry is targeting the end of the year to introduce a free medical coverage plan for those in the bottom 40 (B40) economic category. Archive image for illustration purposes only. Pix courtesy of UNIMAP

By AUDREY VIJAINDREN - August 10, 2018 @ 12:33pm

KUALA LUMPUR: The Health Ministry is targeting the end of the year to introduce a free medical coverage plan for those in the bottom 40 (B40) economic category.
Of the only 30 per cent of Malaysians with some form of medical health insurance, 15 per cent purchased their own medical plan, while between 10 and 15 per cent are covered by their employers.
“Sooner or later, we will have to implement some sort of social health insurance for all Malaysians, but we will start with the B40 group.
“If we are able to cover the bottom 40 per cent, a large proportion of the population will at least have some form of health coverage. Once that is done, we can look into universal coverage for all Malaysians.
“However, we have to work out the details about where the money is going to come from. One of the models proposed is very minimal coverage – for example, RM10,000, so the premiums are low enough to sustain.
“Eventually, we will have to discuss this matter with all stakeholders before we firm up a proposal,” said Deputy Minister of Health Dr Lee Boon Chye.
He said this at after opening the Excellence in Breast Cancer Therapy and Support Conference in Nexus Bangsar South here, today.
Also present at the three-day conference was Pink Ribbon Wellness (L) Foundation founder and chairman, Datuk Dr Devanand; and Beacon Hospital medical director and consultant clinical oncologist, Datuk Dr Mohamed Ibrahim Wahid.
The cost of medical treatment is Malaysia is becoming a burden thanks to inflation of between 10 and 15 per cent annually, which is due to the country’s ageing population, the availability of new treatments and technologies which are expensive, and higher expectations of the efficacy of medical treatment by the community.
“At the end of the day, the Health Ministry will have to look at the cost effectiveness of treatments and try our very best to bring down the price.


#######
“We have successfully reduced the price of Hepatitis C therapy from RM128,000 to below RM1,500 by using generic drugs. We had a strong argument because it is a contagious disease, so we could use that argument to ‘arm-twist’ the multi-national drug companies.

“It’s more difficult with the treatment of cancer, but at the end of the day, if we are unable to reduce the cost, we will have to look at using more generic drugs as an alternative,” Dr Lee added.
#########



The conference is highlighting alarming statistics, including that one in 19 women will develop breast cancer in their lifetime; and that breast cancer is the leading cause of cancer deaths in women under the age of 40.
30/08/2018 11:20
Thkent91 Slow and steady. See you at rm6 in another 4 years time
22/09/2018 00:14
trulyinvest bought 3.24
24/09/2018 10:55
trulyinvest sold 3.28 thx
25/09/2018 09:17
eriktime 3.50 very soon
01/10/2018 18:28
moven00 Hopeful the coming quarter result will be favorable and more contribution to come from Vietnam and Indonesia biz
17/10/2018 08:19
Davidl Hey guys, I join de boat today! Cheers!
21/11/2018 13:22
trulyinvest i oso joined. 2.98
21/11/2018 13:51
Davidl Qtr result good! Time for empire strikes back!
21/11/2018 18:09
moven00 Good...good...
21/11/2018 19:38
trulyinvest So so only I think
21/11/2018 19:43
Davidl The group is cautiously optimistic of maintaining the financial performance toward the end of the year.
22/11/2018 00:06
wwwcomment Is good to accumulate.
22/11/2018 10:32
Davidl AHIB: We continue to like YSP for its bargain valuations against the backdrop of the coming favourable healthcare policy, which we think could benefit generic drug producers such as YSP. Higher export-oriented exposure (38% of total revenue by 2020E), underpinning YSP’s prospects for the foreseeable future, is a boon as well!
23/11/2018 12:58


 

217  221  461  1311 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 MYEG 0.92+0.08 
 ARMADA 0.185+0.01 
 HUBLINE 0.040.00 
 HSI-H4O 0.255-0.05 
 HSI-C3X 0.625+0.06 
 HSI-C3W 0.345+0.04 
 HSI-C3V 0.175+0.025 
 A50CHIN-C26 0.32+0.03 
 HSI-H4V 0.145-0.02 
 PERMAJU 0.380.00 
Partners & Brokers